Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKesson
US Army
Chubb
Merck
Citi
Moodys
Baxter
Express Scripts

Generated: April 19, 2018

DrugPatentWatch Database Preview

Methylnaltrexone bromide - Generic Drug Details

« Back to Dashboard

What are the generic sources for methylnaltrexone bromide and what is the scope of methylnaltrexone bromide patent protection?

Methylnaltrexone bromide
is the generic ingredient in one branded drug marketed by Salix Pharms and Salix Pharms Inc, and is included in two NDAs. There are eleven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Methylnaltrexone bromide has one hundred and twelve patent family members in thirty-six countries.

There are three drug master file entries for methylnaltrexone bromide. One supplier is listed for this compound.
Summary for methylnaltrexone bromide
Pharmacology for methylnaltrexone bromide
Ingredient-typeQuaternary Ammonium Compounds
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for methylnaltrexone bromide
(17R)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6- oxomorphinanium bromide
(17R)-Methylnaltrexone bromide
(17RS)-17-(Cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-17-methyl-6- oxomorphinanium bromide
(17S)-N-Methylnaltrexone bromide
(1S,5R,13R,17S)-4-(CYCLOPROPYLMETHYL)-10,17-DIHYDROXY-4-METHYL-14-OXO-12-OXA-4-AZAPENTACYCLO[9.6.1.0(1),(1)(3).0?,(1)?.0?,(1)?]OCTADECA-7(18),8,10-TRIEN-4-IUM BROMIDE
(5|A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium Bromide
(R)-N-Methylnaltrexone bromide
(R)-Naltrexone methobromide
(R)-Naltrexone methylbromide
(S)-Naltrexone methobromide
1055877-28-5
1378943-67-9
17-(cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium bromide
3844AH
73232-52-7
916045-21-1
916055-92-0
AKOS015896214
AN-37324
BC276097
C21H26NO4.Br
CDW853B60I
CHEMBL1201770
CHIR-01020
CS-0762
D03YVO
D06618
D0A6EE
HY-75766
I06-1616
IFGIYSGOEZJNBE-KNLJMPJLSA-N
Methylnaltrexone (Bromide)
Methylnaltrexone bromide (JAN/USAN)
Methylnaltrexone bromide [USAN:INN:BAN]
Methylnaltrexone bromide, (17S)-
Methylnaltrexone bromide, >=97% (HPLC)
Methylnaltrexone bromide, United States Pharmacopeia (USP) Reference Standard
MNTX
MNTX-302
MOA 728
MOA-728
Morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17S)-
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17- methyl-6-oxo-,bromide,(5alpha)-
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5alpha)-
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,9-dihydroxy-17-methyl-6-oxo-, bromide (1:1), (17S)-
MRZ 2663BR
MRZ-2663BR
N-Cyclopropylmethyl-noroxymorphone Methobromide
N-Methyl Naltrexone Bromide
N-Methylnaltrexone Bromide
Naltrexone (R)-methobromide
Naltrexone (S)-methobromide
Naltrexone methobromide
Naltrexone Methyl Bromide
ONO-3849
PL008834
Relistor
Relistor (TN)
RFO6IL3D3M
SCHEMBL2798188
ST51053157
UNII-CDW853B60I
UNII-RFO6IL3D3M
UNII-RFO6IL3D3M component IFGIYSGOEZJNBE-LHJYHSJWSA-N
UNII-RFO6IL3D3M component IFGIYSGOEZJNBE-NQMNLMSRSA-N
W-5330

US Patents and Regulatory Information for methylnaltrexone bromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-003 Sep 27, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for methylnaltrexone bromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for methylnaltrexone bromide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,455,644 Peripheral opioid receptor antagonists and uses thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cipla
Chubb
Dow
Covington
Cantor Fitzgerald
Baxter
Citi
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.